rs12067569 (PCSK9): LDL Cholesterol and Heart Risk

Key takeaways

• This variant is a genetic proxy for PCSK9, a protein that controls LDL cholesterol receptor activity in the liver
• Genetically predicted PCSK9 inhibition shows strong evidence of reducing coronary artery disease risk
• The metabolic fingerprint of PCSK9 inhibition mirrors statin therapy across 249 blood traits (r2 = 0.91, n up to 115,082)
• LDL-lowering genetic scores including PCSK9 have weak effects on a circulating inflammation marker, unlike triglyceride-targeting scores
• The ALT allele reduces USP24 gene expression across six tissue types including skin, breast, and arterial tissue

What the research says rs12067569 lies near PCSK9, a gene whose protein product controls circulating LDL cholesterol by targeting LDL receptors on liver cells for degradation - fewer receptors means more LDL remains in the bloodstream. A Mendelian randomization (MR) study, an approach that uses genetic variants as natural experiments to infer causal biological effects, constructed a genetic instrument for PCSK9 inhibition from UK Biobank data and found strong evidence of reduced coronary artery disease (CAD) risk, with metabolomic effects across 249 blood traits correlating at r2 = 0.91 with those of a genetic instrument for statin therapy in up to 115,082 participants. GTEx tissue-expression data additionally show that the ALT allele of rs12067569 is associated with reduced expression of USP24 (ubiquitin-specific peptidase 24, a protease involved in recycling damaged proteins in cells) across six tissues, with the strongest reduction in unexposed suprapubic skin GTEx Portal.

Reported associations

• LDL cholesterol: Variants near PCSK9 (P < 1e-6, within 100 kb of the gene) were selected as genetic instruments for LDL cholesterol using a UK Biobank GWAS of 328,111 participants
• Coronary artery disease (CAD) risk: Mendelian randomization found strong evidence that the PCSK9 genetic score reduces CAD risk, consistent with the known clinical effects of PCSK9-inhibiting drugs
• Blood metabolome (249 traits): The PCSK9 genetic instrument produced metabolomic effects correlating closely with those of the statin (HMGCR) genetic instrument (r2 = 0.91 across 249 traits, n up to 115,082); both contrast sharply with triglyceride-targeting genetic scores, which showed r2 < 0.02 vs. HMGCR for each of four triglyceride-targeting drug targets
• Glycoprotein acetyls (inflammation marker): PCSK9 and statin genetic scores showed weak effects on this circulating inflammation marker, whereas genetic scores for triglyceride-modifying drugs showed strong effects on the same trait
• USP24 expression: The ALT allele is associated with reduced USP24 expression across unexposed suprapubic skin, esophageal gastroesophageal junction, breast mammary tissue, tibial nerve, sun-exposed lower-leg skin, and tibial artery (slopes ranging from -0.28 in unexposed skin to -0.15 in tibial artery, log2-normalized; p-values from 5.7e-8 to 1.5e-4) GTEx Portal

Evidence quality The Mendelian randomization analysis used UK Biobank data with a LDL cholesterol GWAS of n = 328,111 and metabolic trait analyses in up to n = 115,082 participants, providing substantial statistical power. The high correlation between PCSK9 and HMGCR genetic instrument effects (r2 = 0.91 across 249 traits) supports the construct validity of using PCSK9-region variants as drug-target proxies. Notably, no direct per-variant association statistics for rs12067569 as a standalone SNP were reported in the provided study; the variant's role is understood as part of the broader PCSK9 gene-region instrument rather than as an individually characterized finding. The genetic instrument selection threshold of P < 1e-6 is moderately strict but below the conventional genome-wide significance level of 5e-8, which is worth noting when interpreting instrument quality. The GTEx eQTL data for USP24 show p-values from 5.7e-8 to 1.5e-4 across six tissues, providing moderate to strong statistical support for tissue-level expression effects. The functional link between reduced USP24 expression and PCSK9-related or cardiovascular biology is not addressed in the provided data and should be regarded as preliminary mechanistic context rather than an established pathway. No conflicts between the provided study and the GTEx data were identified; however, only one primary MR study was available for the PCSK9 drug-target findings, so independent replication of the specific metabolomic correlations has not been assessed from the provided sources.

Tissue-specific expression effects

• USP24: The ALT allele is associated with reduced expression of this ubiquitin-specific protease gene across six tissues - unexposed suprapubic skin (slope -0.28, strongest reduction), esophageal gastroesophageal junction (slope -0.24), breast mammary tissue (slope -0.18), tibial nerve (slope -0.18), sun-exposed lower-leg skin (slope -0.16), and tibial artery (slope -0.15) - a pattern spanning skin, mucosal, glandular, neural, and vascular tissue types GTEx Portal

Lifestyle considerations No lifestyle considerations on file for this variant.